

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

M14

RRID:CVCL_1395

Type: Cell Line

Proper Citation

RRID:CVCL_1395

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1395

Proper Citation: RRID:CVCL_1395

Description: Cell line M14 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: [PMID:56444](#), [PMID:204583](#), [PMID:945229](#), [PMID:954005](#), [PMID:1260767](#), [PMID:1918136](#), [PMID:2041050](#), [PMID:2060184](#), [PMID:3046746](#), [PMID:3658923](#), [PMID:3674770](#), [PMID:6470027](#), [PMID:6500744](#), [PMID:6876798](#), [PMID:8618233](#), [PMID:8631022](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:11121133](#), [PMID:12068308](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:18277095](#), [PMID:19372543](#), [PMID:19549886](#), [PMID:19727395](#), [PMID:19799798](#), [PMID:21863025](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28940260](#), [PMID:29492214](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31733513](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: M14

Synonyms: M14-MEL, UCLA-SO-M14, UCLA SO M14, UCLA-SO-14, UCLASO-M14, Melanoma 14, M-14

Cross References: BTO:BTO_0002805, EFO:EFO_0003056, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioSample:SAMN06129842, cancercellines:CVCL_1395, Cell_Model_Passport:SIDM00003, ChEMBL-Cells:ChEMBL3307591, ChEMBL-Targets:ChEMBL614317, CLS:302163, Cosmic:686479, Cosmic:687445, Cosmic:875889, Cosmic:897467, Cosmic:905975, Cosmic:974068, Cosmic:974261, Cosmic:1022278, Cosmic:1044265, Cosmic:1092611, Cosmic:1109808, Cosmic:1132591, Cosmic:1158815, Cosmic:1295340, Cosmic:1303040, Cosmic:1305365, Cosmic:1312348, Cosmic:1459642, Cosmic:1537485, Cosmic:1888913, Cosmic:1998453, Cosmic:2791112, Cosmic-CLP:905975, DepMap:ACH-002159, EGA:EGAS00001000978, GDSC:905975, GEO:GSM2140, GEO:GSM50201, GEO:GSM50263, GEO:GSM188222, GEO:GSM188252, GEO:GSM188311, GEO:GSM743464, GEO:GSM750799, GEO:GSM799352, GEO:GSM799415, GEO:GSM844583, GEO:GSM847034, GEO:GSM1153422, GEO:GSM1178326, GEO:GSM1178327, GEO:GSM1181292, GEO:GSM1181336, GEO:GSM1670072, GEO:GSM2124668, IARC_TP53:18085, NCI-DTP:M14, PharmacDB:M14_879_2019, PRIDE:PXD003539, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, Progenetix:CVCL_1395, PubChem_Cell_line:CVCL_1395, SKY/M-FISH/CGH:2813, Wikidata:Q51838638

ID: CVCL_1395

Record Creation Time: 20220427T220740+0000

Record Last Update: 20260815T234530+0000

Ratings and Alerts

No rating or validation information has been found for M14.

No alerts have been found for M14.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shi HZ, et al. (2026) BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(28), e14590.

Nicolini F, et al. (2025) Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients. *Frontiers in immunology*, 16, 1636722.

Kim DY, et al. (2025) Identification of UBE3C as an E3 ubiquitin ligase for mutant BRAF. *Life sciences*, 378, 123827.

Kosharek AT, et al. (2025) In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma. *PloS one*, 20(8), e0330200.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Park JA, et al. (2023) Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. *Journal for immunotherapy of cancer*, 11(3).

Tao L, et al. (2023) Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma. *Frontiers in cell and developmental biology*, 11, 1171047.

Park JA, et al. (2022) Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. *Journal for immunotherapy of cancer*, 10(1).

Kline CD, et al. (2022) MITF Is Regulated by Redox Signals Controlled by the Selenoprotein Thioredoxin Reductase 1. *Cancers*, 14(20).

Park JA, et al. (2021) Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. *Journal of hematology & oncology*, 14(1), 142.

Zavareh RB, et al. (2021) HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. *Cell chemical biology*, 28(2), 158.

Lim J, et al. (2019) Kazinol U inhibits melanogenesis through the inhibition of tyrosinase-related proteins via AMP kinase activation. *British journal of pharmacology*, 176(5), 737.

Wallstabe L, et al. (2018) CAR T cells targeting $\alpha\text{v}\beta 3$ integrin are effective against advanced cancer in preclinical models. *Advances in cell and gene therapy*, 1(2).